EL
ELXMF.US Nova Eye Medical Limited
- Market cap
- USD 4.08M
- P/E
- -
- P/B
- 0.37x
- ROE
- -30.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ELXMF.US undervalued?
Graham numberThe Graham number of Nova Eye Medical Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nova Eye Medical Limited fundamental analysis
No fundamental analysis for Nova Eye Medical Limited yet.
Nova Eye Medical Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nova Eye Medical Limited
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucom…
Full company profileNova Eye Medical Limited financial statements
Nova Eye Medical Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 71.8M | 79.4M | 16.1M | 12.8M | 13.4M | 13.4M | 17.0M | 23.3M | 29.3M | 34.8M |
| Gross Profit | 41.0M | 46.4M | 13.2M | -1.64M | 1.77M | -765K | 842K | 20.2M | 18.9M | 25.0M |
| Operating Income | -81.0K | -3.53M | -7.05M | -7.18M | -4.97M | -6.59M | -11.8M | -8.97M | -4.50M | -4.37M |
| EBITDA | 1.51M | -1.54M | -4.22M | -5.75M | -3.45M | -7.89M | -9.48M | -5.98M | -6.72M | -2.20M |
| Net Income | -894K | -5.07M | -6.66M | -6.99M | -4.36M | -7.50M | -15.3M | -8.79M | -9.06M | -4.33M |
| EPS | -0.01 | -0.04 | -0.05 | -0.05 | -0.03 | -0.05 | -0.10 | -0.04 | -0.04 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 86.5M | 103M | 99.9M | 117M | 42.0M | 36.6M | 30.4M | 29.9M | 26.5M | 21.6M |
| Total Liabilities | 29.6M | 30.2M | 31.1M | 16.2M | 6.66M | 6.23M | 7.17M | 8.55M | 7.54M | 7.30M |
| Shareholders' Equity | 56.9M | 73.2M | 68.8M | 101M | 35.3M | 30.4M | 23.2M | 21.3M | 19.0M | 14.3M |
| Cash & Short-term Investments | 9.24M | 23.1M | 15.4M | 95.6M | 17.8M | 8.00M | 7.42M | 6.15M | 5.06M | 963K |
| Total Debt | 15.6M | 15.0M | 15.1M | 3.34M | 3.70M | 1.94M | 1.53M | 3.35M | 3.02M | 2.39M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.50M | 522K | -4.21M | 5.45M | -12.9M | -4.68M | -6.72M | -7.86M | -6.15M | -3.12M |
| Capital Expenditure | 7.06M | 2.64M | 726K | 1.66M | 2.23M | 5.59M | 800K | 449K | 298K | 235K |
| Free Cash Flow | -10.6M | -2.12M | -4.93M | 3.79M | -15.1M | -10.3M | -7.52M | -8.31M | -6.45M | -3.35M |
| Ratios | ||||||||||
| ROE | -1.6% | -6.9% | -9.7% | -7.0% | -12.3% | -24.7% | -65.9% | -41.2% | -47.8% | -30.4% |
| ROA | -1.0% | -4.9% | -6.7% | -6.0% | -10.4% | -20.5% | -50.4% | -29.4% | -34.2% | -20.1% |
| Net Profit Margin | -1.2% | -6.4% | -41.3% | -54.7% | -32.5% | -56.0% | -89.8% | -37.7% | -31.0% | -12.4% |
| Debt to Equity | 0.27x | 0.20x | 0.22x | 0.03x | 0.10x | 0.06x | 0.07x | 0.16x | 0.16x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nova Eye Medical Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 21, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | AUD 19.4M | 0.13 | - |
| 2020 | AUD 19.4M | 0.13 | - |
| 2019 | AUD 19.4M | 0.13 | - |
| 2018 | AUD 19.4M | 0.14 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Nova Eye Medical Limited
- Insiders 18.88%
- Institutions 18.23%
- Public & others 62.89%
- Shares outstanding 285M
- Free float 223M
Nova Eye Medical Limited company profile
- Company name
- Nova Eye Medical Limited
- Ticker
- ELXMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 107 Rundle Street, Kent Town, SA, Australia, 5067
- Phone
- 61 8 8362 0193
- Website
- nova-eye.com
About Nova Eye Medical Limited
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
Nova Eye Medical Limited management
10- Mr. Victor PrevinFounder & Chairman · born 1958
- Mr. Thomas H. Spurling AM, BSc (Hons), FRACI, FTSE, Ph.D.MD & Executive Director · born 1962
- Ms. Kimberley MenziesChief Financial Officer
- Mark FlynnInvestor Relations
- Ms. Kate HuntChief Commercial Officer
- Mr. Joe BankovichPresident of Global Sales
- Mr. Joaquin V. WolffPresident of Ellex iTrack · born 1958
- Mr. Simon Jeremy Newton Gray BEc, C.A.Company Secretary · born 1959
- Jordan PossinghamFinancial Controller
- Mr. Don WattonVice President of Global Service